Reasons to invest

Investment Highlights

Proven Technologies

Used in over 150,000 patients worldwide, with proven safety and effectiveness supported by clinical studies.

Full in-house capabilities

Full control across R&D, manufacturing, and commercialization, enabling efficient development, high quality, and faster market access.

Core Technologies Driving Better Care

We advance patient care through Degradable Starch Microspheres (DSM), Amniotic-Based Stem Cells, and Dextran Derivatives.

The Magle Advantage

Innovation with Measurable Impact

At Magle Group, innovation is not just an ambition, it’s the core of our identity. Our CDMO services, help our customers develop and deliver of innovative therapies. We develop and commercialize technologies grounded in science and validated through clinical evidence. Our proprietary Degradable Starch Microsphere (DSM) technology is already used in several approved products and has benefited more than 150,000 patients worldwide. With additional platforms in dextran and amniotic stem cells, we are expanding into high-impact areas such as oncology, wound care, immunotherapy, and regenerative medicine.

End-to-End Operational Excellence

At Magle Group, we manage the full development lifecycle in-house, from early research and upscaling to commercial manufacturing and sales. Our integrated capabilities span quality assurance, regulatory compliance, logistics, and clinical trials. This end-to-end control ensures consistently high standards of quality, efficiency, and speed, positioning Magle Group as a reliable and forward-looking partner in the healthcare sector.

Uncompromising Commitment to Quality

At Magle Group, quality is embedded in every stage of our work, from early research through to final product delivery. Our fully integrated operations allow us to oversee and uphold high standards across development, clinical evaluation, manufacturing, and distribution. With dedicated teams for quality assurance, regulatory affairs, and process control, we ensure that every product meets stringent internal benchmarks for safety, performance, and reliability. This commitment to excellence not only supports better outcomes for patients but also builds lasting confidence among partners, healthcare professionals, and customers.

Clear growth strategy

We are an ambitious growth company with a clear strategy for future growth. This strategy means developing new products and applications and expanding into both new and existing markets. In 2021 we started work on building a scalable direct sales organisation for Europe. Through the acquisition of PharmaCept we have gained a well-established sales organisation in Europe.

Magle Group has expanded its life science portfolio through the acquisition of Amniotics AB, bringing advanced amniotic stem cell technologies into its pipeline. Additionally, the acquisition of PKC enhances Magle’s capabilities in contract manufacturing and sterile production, strengthening its integrated CDMO offering.

Recent Strategic Milestone

Interested in Learning More

Whether you’re a potential investor, analyst, or stakeholder looking to understand our long-term value, we welcome the opportunity to connect.

Visit our Investor Contacts page to get in touch with our team for further information, investor materials, or to schedule a meeting.